protac compounds (Arvinas Inc)
86
Structured Review
Arvinas Inc
protac compounds
Protac Compounds, supplied by Arvinas Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protac+compounds/protac+technology/pm42150270-138-40-33
Average 86 stars, based on 1 article reviews
Protac Compounds, supplied by Arvinas Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protac+compounds/protac+technology/pm42150270-138-40-33
Average 86 stars, based on 1 article reviews
protac compounds - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: Development of tau-directed small molecule modulators for Alzheimer's disease: a recent patent review (2014-2018). Article Snippet: Ha E Lee‡ ,1,2, Dami Lim‡ ,1,3, Jae Y Lee3, Sang M Lim**,1,2 & Ae N Pae*,1,2,3 1Convergence Research Center for Diagnosis, Treatment & Care System of Dementia, Korea Institute of Science & Technology, Seoul 02792, Republic of Korea 2Division of Bio-Medical Science & Technology, KIST School, Korea University of Science & Technology, Seoul 02792, Republic of Korea 3KHU-KIST Department of Converging Science & Technology, Kyung Hee University, Seoul 02447, Republic of Korea *Author for correspondence: anpae@kist.re.kr **Author for correspondence: smlim28@kist.re.kr ‡Authors contributed equally Clinical Proteomics:Article Title: Targeted protein degradation: A new direction for treatment of diseases Article Snippet: .. The first PROTAC compounds are in clinical trials, developed by the leading Activity Assay:Article Title: PROTACs for central nervous system disorders: challenges and opportunities. Article Snippet: Central nervous system (CNS) disorders, particularly neurodegenerative diseases and brain tumors, pose substantial and long-standing challenges to the global public health system.. Current therapeutic approaches for CNS disorders are primarily confined to symptomatic relief and generally fail to halt or reverse disease progression.. However, proteolysis-targeting chimeras (PROTACs), as an emerging therapeutic strategy, have introduced new prospects for effective intervention in this domain. |